CD 20

This test is a blood test performed using flow cytometry to measure the presence and levels of CD20-positive B cells, a type of white blood cell involved in the immune system. CD20 is a surface marker found on B lymphocytes.

The purpose of this test is to:

• Measure CD20-positive B cell levels
• Assist in diagnosing lymphoma and leukemia
• Evaluate immune system function
• Monitor response to B-cell targeted therapies
• Support assessment of hematological disorders

CD 20 Test Purpose

The CD20 Test measures the presence and expression of CD20, a protein found on the surface of mature B lymphocytes (B cells), using flow cytometry or other immunophenotyping techniques. CD20 plays an important role in B-cell development and immune function. The test is primarily used to evaluate B-cell lymphoproliferative disorders, diagnose certain blood cancers, and monitor the effectiveness of B-cell-targeted therapies.

Healthcare providers commonly recommend the CD20 Test for individuals with persistent swollen lymph nodes, unexplained fever, night sweats, unexplained weight loss, recurrent infections, abnormal blood counts, or suspected leukemia or lymphoma. It is also performed as part of the diagnostic workup for patients with suspected non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and other B-cell malignancies.

Furthermore, the CD20 Test helps identify CD20-positive B cells, which are present in most mature B-cell lymphomas and leukemias. It is particularly valuable in determining whether a patient is likely to benefit from anti-CD20 monoclonal antibody therapies, such as rituximab, obinutuzumab, or ofatumumab. Reduced or absent CD20 expression may occur after B-cell-targeted treatment or in certain types of leukemia and lymphoma. However, CD20 results alone are not sufficient to establish a diagnosis and should always be interpreted alongside clinical findings and additional laboratory investigations.

The CD20 Test is often performed together with CD19, CD3, CD4, CD8, CD45, Complete Blood Count (CBC), Bone Marrow Examination, Flow Cytometry Immunophenotyping, Immunohistochemistry (IHC), Cytogenetic Analysis, and Molecular Testing to provide a comprehensive evaluation of hematological disorders.

The test results should always be interpreted together with the patient’s symptoms, medical history, physical examination, imaging findings, and other laboratory investigations. Serial CD20 assessments may also help monitor disease progression and response to therapy.

CD 20 Test is Recommended for Individuals:

• Individuals with suspected B-cell leukemia or lymphoma.
• Patients with persistent enlarged lymph nodes or abnormal blood counts.
• People undergoing evaluation for non-Hodgkin lymphoma (NHL).
• Individuals receiving anti-CD20 therapies such as rituximab.
• Patients requiring immunophenotyping of blood or bone marrow cells.
• Individuals with suspected B-cell lymphoproliferative disorders.
• Patients advised by their hematologist or oncologist to undergo CD20 testing.

FAQs

1. What is the CD20 Test used for?

The CD20 Test detects CD20 protein on B lymphocytes. It is used to diagnose B-cell leukemias and lymphomas, classify hematological cancers, and determine eligibility for anti-CD20 therapies.

2. Do I need to fast before the CD20 Test?

No, fasting is generally not required for the CD20 Test. However, always follow any specific instructions provided by your healthcare provider before sample collection.

3. What do abnormal CD20 Test results mean?

Abnormal CD20 expression may indicate B-cell leukemia, non-Hodgkin lymphoma, other B-cell lymphoproliferative disorders, or changes following anti-CD20 therapy. Your healthcare provider will interpret the results together with your symptoms, medical history, flow cytometry findings, and other laboratory investigations to determine the underlying condition and recommend appropriate treatment.